Shanghai, China – December 15, 2025 – MicroPort Scientific Corporation (00853.HK, “MicroPort®”) today announced that the strategic merger between its subsidiaries MicroPort CardioFlow Medtech Corporation (02160.HK, "MicroPort® CardioFlow") and MicroPort® Cardiac Rhythm Management ("MicroPort® CRM") has been approved by MicroPort® CardioFlow’s shareholders. MicroPort® CardioFlow will acquire MicroPort® CRM through a non-cash transaction, issuing new shares with a total consideration of USD 680 million.
The merger aims to integrate core strengths across structural heart intervention and cardiac rhythm management. It seeks to address the complex diagnostic and treatment needs covering all causes and stages of heart failure, and to develop a global, specialized device platform for heart failure that spans the entire process of monitoring, diagnosis, treatment, and management.
Currently, the company has a rich pipeline in development covering the full cycle of heart failure management. The first heart failure product post-merger - IABP (Intra-Aortic Balloon Pump) - is expected to be approved in China in 2026.
Heart failure is not a single disease, but rather a complex clinical syndrome resulting from various factors that cause structural and/or functional abnormalities of the heart, impairing ventricular systolic and/or diastolic function. It encompasses four stages: the pre‑heart failure risk stage, early heart failure, symptomatic heart failure, and end‑stage heart failure. Globally, over 64 million people are affected by heart failure1. However, despite the large patient base and complex etiological landscape, device-based therapies in heart failure remains relatively limited. Current device applications are predominantly concentrated in patients with end-stage heart failure, while there is insufficient coverage in key areas such as prevention, assessment, and monitoring for the larger proportion of patients in the early and intermediate stages.
Through this integration, MicroPort® will make a strategic entry into heart failure, one of the highest-potential value segments within the cardiovascular disease landscape. By combining MicroPort® CRM’s strengths in AI-enabled diagnostics and algorithm development with MicroPort® CardioFlow’s deep expertise in structural heart interventions, precision delivery systems, biomaterials and hemodynamic platforms, the company possesses not only technological reserves but also capabilities that have been validated through long-term market and clinical practice. This provides solid support for building a comprehensive device-based diagnosis and treatment system for heart failure, one that addresses all etiologies, covers all stages of the disease course, and spans the entire process of monitoring, diagnosis, treatment, and management.
At the same time, the strategic merger represents a key step in MicroPort®’s efforts to optimize resource allocation and enhance its overall competitiveness. It provides a solid foundation for cultivating a world-leading cardiovascular platform and injects strong momentum into the company’s long-term, high-quality growth, as reflected in the following aspects:
Portfolio Integration and Global Expansion: Product pipeline integration will enable a more comprehensive and rich product portfolio across structural heart disease and cardiac rhythm management, supporting broader hospital coverage and accelerating global market penetration through MicroPort® CRM's mature sales channels.
Global Resource Alignment and Operational Synergies: The merger strengthens global collaboration across sales, distribution, and operational infrastructure. Leveraging MicroPort® CRM's established operational teams and infrastructure is expected to improve localized operations in clinical development, quality systems, and customer support.
R&D Collaboration and Supply Chain Integration: Combined R&D capabilities will support deeper technology integration and innovation. Supply chain integration will enhance economies of scale, strengthen resilience, and mitigate sourcing risks through diversified manufacturing and supplier networks.
Looking ahead, the combined company will prioritize end-to-end comprehensive heart failure care as a core strategic focus and aims to build a globally leading platform capable of delivering end-to-end, integrated solutions across the full care continuum. This strategy will provide sustained momentum for MicroPort®’s long-term advancement in major disease areas.
This initiative represents not only a significant milestone in MicroPort®’s heart failure journey, but also a concrete step in fulfilling the company’s purpose of “Pushing boundaries so that patients everywhere can enjoy better and longer lives” by providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives.
Shahim, Bahira, et al. “Global Public Health Burden of Heart Failure: An Updated Review.” Cardiac Failure Review, vol. 9, e11, 2023, doi:10.15420/cfr.2023.05.
About MicroPort®
Since 1998, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can live better and longer lives. As a global medical device company, MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, endovascular, neurovascular and surgical robotics. Serving over 100 countries and 20,000 hospitals, MicroPort® provides a medical solution to a patient every 5 seconds.
More information is available at www.microport.com.
About MicroPort® CardioFlow
MicroPort® CardioFlow is an innovation leader in the global structural heart disease interventional treatment field. It holds a leading position in the Chinese transcatheter aortic valve implantation (TAVI) market and has officially entered a new phase of scaled global operations and high-quality development. Through independent R&D and collaborative development with global partners, MicroPort® CardioFlow has built a forward-looking innovative pipeline covering transcatheter solutions for aortic, mitral, and tricuspid valve diseases, interventional treatment for post-myocardial infarction ventricular septal defects, and stroke prevention related to atrial fibrillation, continuously leading industry technological innovation and global market expansion.
More information is available at: https://en.cardioflowmedtech.com/
About MicroPort® CRM:
MicroPort® CRM is a global leader in the field of cardiac rhythm management, headquartered in Clamart, near Paris, France. With more than 60 years of expertise and continuous innovation, MicroPort® CRM currently boasts 12 pipelines and over 40 marketed products across core cardiac rhythm management segments, including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) systems, and Holter ECG diagnostic solutions.
More information is available at www.microport.com.